R&D tax credit would be made permanent by twin bills in House and Senate.
R&D TAX CREDIT WOULD BECOME PERMANENT UNDER HOUSE & SENATE BILLS introduced by Rep. Johnson (R-Conn.) Feb. 2 and Sen. Hatch (R-Utah) Feb. 3. The bills -- HR 803 and S 351 -- are worded identically to "amend the Internal Revenue Code of 1986 to make permanent the credit for increasing research activities."
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth